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Abstract
Introduction
Substance use is associated with common mental health disorders, but the causal effect of
specific substances is uncertain. We investigate whether adolescent cannabis and cigarette
use is associated with incident depression and anxiety, while attempting to account for con-
founding and reverse causation.
Methods
We used data from ALSPAC, a UK birth cohort study, to investigate associations between
cannabis or cigarettes (measured at age 16) and depression or anxiety (measured at age
18), before and after adjustment for pre-birth, childhood and adolescent confounders. Our
imputed sample size was 4561 participants.
Results
Both cannabis (unadjusted OR 1.50, 95% CI 1.26, 1.80) and cigarette use (OR 1.37, 95%
CI 1.16, 1.61) increased the odds of developing depression. Adjustment for pre-birth and
childhood confounders partly attenuated these relationships though strong evidence of as-
sociation persisted for cannabis use. There was weak evidence of association for cannabis
(fully adjusted OR 1.30, 95% CI 0.98, 1.72) and insufficient evidence for association for cig-
arette use (fully adjusted OR = 0.97, 95% CI 0.75, 1.24) after mutually adjusting for each
other, or for alcohol or other substance use. Neither cannabis nor cigarette use were associ-
ated with anxiety after adjustment for pre-birth and childhood confounders.
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Conclusions
Whilst evidence of association between cannabis use and depression persisted after ad-
justing for pre-term and childhood confounders, our results highlight the difficulties in trying
to estimate and interpret independent effects of cannabis and tobacco on psychopathology.
Complementary methods are required to robustly examine effects of cannabis and tobacco
on psychopathology.
Background
A variety of mental health problems, including depression and anxiety, occur more commonly
in substance users than non-users.[1–4] However, discerning causation from confounding, re-
verse causation, or selection or measurement bias in observational studies is problematic.[5]
The cannabinoid system in the brain has been implicated in emotional regulation,[6] but bio-
logical mechanisms that might underlie the association between cannabis use and depression
are not known, and indeed effects of cannabis may differ between the short and long term. For
example, while people often report that cannabis acutely elevates their mood, long-term canna-
bis users show an increased risk of a number of adverse outcomes, including poorer education
and social functioning,[7] which might be expected to increase risk of depression.
A recent systematic review and meta-analysis of longitudinal studies reported a 1.17-fold in-
crease in odds of depression (95% CI 1.05, 1.30) in cannabis users, with a larger effect
(OR = 1.62, 95% CI 1.21, 2.16) for heavy use,[8] and concluded that cannabis is associated with
a modest increase in risk of developing depressive disorders. An earlier meta-analysis reported
a similar association, but the authors argued that the majority of contributing studies did not
adequately account for the possibility of reverse causation.[9] They also noted the wide varia-
tion in the number and type of confounders adjusted for. In particular, about half the studies
included in their meta-analysis made no adjustment for alcohol or other drug use, which,
given their potential depressogenic and anxiogenic effects during intoxication and withdrawal,
[10, 11] strongly suggests the potential for residual confounding. Similar problems are likely to
exist for determining the causal role of cannabis on anxiety.[9]
Tobacco use is also more common in people with depression and anxiety compared to the
general population,[1, 3] and determining if these associations are causal is beset with the same
difficulties as for cannabis. Whilst some studies indicate that smoking may be a self-medication
behaviour,[12] other studies provide evidence in support of a biological causal mechanism for
this association. For example, findings from animal studies suggest that nicotine effects on
strengthening excitatory synapses on midbrain dopamine neurons might weaken coping
mechanisms.[13]
The main aim of this study was to investigate the association between cannabis and cigarette
use and incident depression and anxiety, whilst attempting to address issues relating to con-
founding, reverse causation and bias as robustly as we could. Furthermore, as cannabis and cig-
arette use are also associated with psychotic experiences (PEs), and we recently reported such
associations within this sample,[14] we also examine the specificity of cannabis and cigarettes
by comparing their effects on depression with those for PEs.
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Methods
Participants
The Avon Longitudinal Study of Parents and Children (ALSPAC) is a prospective, population-
based birth cohort study that recruited 14,541 pregnant women resident in Avon, UK, with ex-
pected delivery dates April 1 1991 to December 31 1992 (http://www.alspac.bris.ac.uk). Infor-
mation has been collected on the participants and their offspring from over 60 questionnaires
and 9 clinic assessments.[15] (http://www.bris.ac.uk/alspac/researchers/data-access/data-
dictionary/). The current study is based on 4,561 individuals who completed the Revised Clini-
cal Interview Schedule (CIS-R) at age 18. Ethical approval for the study was obtained from the
ALSPAC Ethics and Law Committee and the Local Research Ethics Committee.
Measures
Exposures. Cannabis and cigarette use at age 16 were measured via self-report question-
naire (N = 5,068 & N = 5,074 respectively). Cumulative cannabis use was coded as a 4 level cat-
egory variable: ‘0 times’, ‘1–20 times’, ‘21–60 times’ and ‘more than 60 times’ (see S1 File for
further details). Frequency of smoking was coded as a 4 level category variable: ‘non-smokers’,
‘experimenters’, ‘weekly smokers’ and ‘daily smokers’.
Outcomes. Depression and anxiety were assessed at age 18 using the CIS-R [16] via a self-
administered computerised interview. The primary outcomes were binary variables of depres-
sion (mild, moderate or severe) and of anxiety disorder (any of generalised anxiety disorder,
social phobia, specific phobia, panic disorder, or agoraphobia) derived from algorithms based
on ICD-10 criteria for unipolar depression and anxiety disorders respectively (see S1 File for
further details).
Confounders. Based on the literature for associations between both cannabis and cigarette
use with depression and anxiety, we considered the following as potential confounders: a) pre-
birth confounders (family history of depression[17] [binary measure assessed via maternal ques-
tionnaire],maternal education[18] [a 5-level categorical variable assessed via maternal ques-
tionnaire], urban living [urban/town/village/hamlet, obtained from postcode of residence], and
gender[19]); and b) childhood confounders (IQ at age 8[20] [assessed via Wechsler Intelligence
Scale for Children[21]], borderline personality traits[22] [an 8-level measure assessed via inter-
view at age 11], victimisation[23] [a binary measure assessed at age 8 via interview], peer prob-
lems[24] [a 10-point scale assessed via the strengths and difficulties interview at age 8[25]], and
conduct disorder trajectory group ages 4–13[26] [membership of one of 4 trajectory paths
(early onset persistent/childhood-limited/adolescent onset/low) as described in[27]]). We also
examined alcohol use[28] [using the Alcohol Use Disorders Identification Test (AUDIT) score
ranging from 0 to 40, assessed via questionnaire[29]] and other illicit drug use[30] [a 3 level
measure none/other drugs/stimulants assessed via questionnaire] at age 16 as potential con-
founders. Cigarette and cannabis use were also considered as confounders for each other.
Statistical analysis
We carried out the analyses in STATA version 13 (Stata Corp LP, College Station, TX USA)
and Mplus. We assessed exposure-outcome relationships before and after adjustment for con-
founders using logistic regression. We excluded individuals with depression (cut-off score of
11 on moods and feelings questionnaire (MFQ)[31, 32]) or anxiety (from DAWBA[33]) at age
16 from the relevant analyses, in order to minimise reverse causation. We examined the impact
of confounding by comparing unadjusted estimates (model 1) with those adjusting for pre-
birth confounders (model 2), and those further adjusted for childhood confounders (model 3).
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Further adjustment was made separately for age 16 cigarette use or cannabis use as appropriate
(model 4a), alcohol use (model 4b), and other illicit drug use (model 4c). Finally, we also ran a
fully adjusted analysis (model 5). This step-wise approach was used to elucidate the impact of
different confounders on the associations.
We used a bivariate probit regression model in Mplus to investigate whether cannabis (or
cigarettes) had similar (or different) effects on depression as they did on PEs, whilst taking into
account their comorbidity. Using Wald tests, we compared a model where effect estimates for
depression and PEs were allowed to differ with one where they were constrained to be the
same. Probit estimates were converted to approximate odds ratios (ORs) to allow for easier in-
terpretation. A binary measure of PEs (suspected or definite versus none) at age 18 was derived
following a semi-structured interview conducted by trained psychologists.[34]
Analytical sample
The complete sample with data on outcomes, exposures and confounders was 1791 (Fig 1). To
address the potential bias introduced by attrition in our sample we conducted multiple imputa-
tion, creating 100 imputed datasets using additional information from over 50 variables associ-
ated with our observed measures and with missingness to make the assumption that data were
‘missing at random’ more plausible. The measures included related to pre-birth factors, child-
hood and adolescent behaviours, and earlier measures of psychopathology and substance use
at various ages. Our primary results are presented using this sample with imputed confounder
Fig 1. Study Participant Flow Diagram.
doi:10.1371/journal.pone.0122896.g001
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and exposure data (imputed sample N = 4561). There were 4345 people who had information
on both depression and PEs at age 18, for the imputed bivariate analysis. Omitting those with
previous depression or anxiety from imputed data is not trivial,[35] therefore the same esti-
mates were obtained using a series of appropriately parameterized interaction models. Pre-
existing depression or anxiety was included as a moderator variable in both the imputation and
the analyses that followed. Given the number of interaction terms required, a separate imputa-
tion model was derived for each exposure/outcome pair in turn.
As a sensitivity analysis we assessed associations in the whole sample (N = 4561), without
excluding those with depression at age 16. We also repeated the main analyses in the complete
case dataset (N = 1512).
Results
Cannabis and depression
There were 128 people (7.2%, 95% CI 6.0, 8.4) who had depression at age 18, 94 females and 34
males. Of our sample with complete data, 491 (27.4%) had ever used cannabis by age 16, and
59 (3.3%) had used more than 60 times. Higher levels of cannabis use were more common in
participants whose mothers had not undertaken higher education, in those with conduct disor-
der and who used other substances, and in those with a higher childhood IQ (Table 1).
In the unadjusted analysis there was a 1.5-fold increase in the odds of depression per catego-
ry increase of cumulative cannabis use (95% CI 1.26, 1.80). Adjustment for childhood con-
founders attenuated the association by approximately 20% though strong evidence of an
association remained (Table 2). Further adjustment for adolescent substance use led to further
attenuation in the size of the association (fully adjusted OR 1.30, 95% CI 0.98, 1.72). This
Table 1. Descriptives of confounders by cumulative cannabis use at age 16% (N).
Cumulative cannabis age 16 0 times 72.4 (1300) <20 times 20.3 (367) 21–60 times 3.8 (65) >60 times 3.6 (59) P value
FH depression 26.2 (341) 29.4 (108) 36.9 (24) 32.2 (19) 0.039
FH schizophrenia 0.8 (10) 1.1 (4) 0 1.7 (1) 0.622
Low Maternal education1 77.7 (1010) 70.3 (258) 61.5 (40) 71.2 (42) 0.001
Urban dwelling 89.2 (1159) 87.5 (321) 89.2 (58) 88.1 (52) 0.573
Gender (female) 57.4 (746) 65.1 (239) 53.9 (35) 45.8 (27) 0.787
Borderline personality2 1.3 (17) 1.1 (4) 1 1.7 (1) 0.700
IQ at age 8 m(sd) 109.1 (15.2) 111.9 (15.6) 115.7 (14.9) 111.9 (13.9) <0.001
Psychotic experiences age 12 3.4 (44) 4.6 (17) 0 5.1 (3) 0.732
Conduct disorder3 5.2 (68) 9.3 (34) 7.7 (5) 15.3 (9) <0.001
Peer problems (4 or more) 7.1 (93) 5.2 (19) 10.8 (7) 8.5 (5) 0.225
Bullied 30.3 (394) 29.7 (109) 29.2 (19) 32.2 (19) 0.976
Cigarette smoking age 164 2.3 (30) 21.3 (78) 40.0 (26) 71.2 (42) <0.001
Illicit drugs age 16 6.2 (80) 32.7 (120) 63.1 (41) 81.4 (48) <0.001
Alcohol use age 165 20.9 (272) 62.9 (231) 61.5 (40) 84.8 (50) <0.001
FH- family history; IQ- intelligence quotient.
1No higher education. Categorised like this for purposes of presentation in this table only.
2Deﬁned as score of 4 or over, for the purposes of presentation in this table only.
3Early onset persistent group membership. Categorised like this for purposes of presentation in this table only.
4Weekly or daily smoking. Categorised like this for purposes of presentation in this table only.
5Hazardous alcohol use. Categorised like this for purposes of presentation in this table only.
doi:10.1371/journal.pone.0122896.t001
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implies an increased risk of depression of 2.2 in the highest category of self-reported cannabis
use (> 60 times) versus never users.
Cigarette use and depression
Of those with complete data, 803 (44.8%) had ever smoked a cigarette, with 99 (5.5%) smoking
every day. Higher frequency of cigarette use occurred in females, and in those with conduct dis-
order and those who used other substances (Table 3).
Cigarette use at age 16 was associated with an increased odds of depression at age 18 (unad-
justed OR per category of cigarette use = 1.37, 95% CI 1.16, 1.61). Adjusting for pre-birth and
childhood confounders attenuated the association by about 50%, though some evidence of an
association persisted (Table 2). Further adjusting for cannabis use eliminated evidence of asso-
ciation between cigarette use and depression, with adjustment for alcohol, or illicit drug use, re-
sulting in similar (though less strongly attenuated) results (fully adjusted OR = 0.97, 95% CI
0.75, 1.24). Cigarette use and cannabis use were correlated (polychoric rho = 0.78, SE 0.01).
Bivariate Analysis
Adjustment for childhood confounders and substance use also attenuated the association be-
tween cannabis or tobacco and psychotic experiences. There was no evidence (Table 4) of dif-
ferences between i) the association between cannabis and depression, and that between
cannabis and PEs (Model 5 Wald test -0.010, p = 0.913), or ii) the association between cigarette
use and depression, and that between cigarettes and PEs (Model 5 Wald test -0.043, p = 0.523).
Anxiety
There were 162 (9.0%, 95% CI 7.8, 10.5) participants in our sample with anxiety at age 18.
There was weak evidence of an association between cannabis use and anxiety disorder at age
Table 2. Logistic regression of intensity of cannabis or cigarette use at age 16 and Depression at age 18 using imputed data (100 imputations), ac-
counting for those with depression at age 16* (N = 4561).
Model Cannabis Cigarettes
OR 95% CI P value OR 95% CI P value
1 1.50 1.26, 1.80 <0.001 1.37 1.16, 1.61 <0.001
2 1.52 1.26, 1.82 <0.001 1.29 1.09, 1.53 0.003
3 1.41 1.17, 1.71 <0.001 1.20 1.01, 1.43 0.033
4a 1.32 1.03, 1.68 0.027 1.11 0.90, 1.38 0.331
4b 1.35 1.09, 1.67 0.006 1.15 0.95, 1.40 0.155
4c 1.38 1.09, 1.75 0.007 1.15 0.95, 1.40 0.153
5 1.30 0.98, 1.72 0.065 1.09 0.87, 1.36 0.460
Model 1—Case depression at 18 by unit increase of 4-level categorical cumulative cannabis or frequency of cigarette use at 16.
Model 2—as model 1 with additional adjustment for pre birth confounders (family history of depression, gender, urban dwelling, maternal education).
Model 3—as model 2 with additional adjustment for childhood confounders (borderline personality, IQ at age 8, PEs at age 12, conduct disorder trajectory
group membership, peer problems, bullied).
Model 4a—as model 3 with additional adjustment for cigarette use/cannabis use (as appropriate).
Model 4b—as model 3 with additional adjustment for alcohol use.
Model 4c—as model 3 with additional adjustment for illicit drug use (other than cannabis).
Model 5—as model 3 with additional adjustment for cigarette (or cannabis), alcohol, other illicit drug use.
* The imputed interaction model allowed us to account for 15% of participants who reported depression at age 16, without exclusions.
doi:10.1371/journal.pone.0122896.t002
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18, but no evidence after adjustment for pre-birth and childhood confounders (S1 Table), and
further attenuation still after adjusting for substance use (unadjusted OR = 1.13, 95% CI 0.98,
1.31; fully adjusted OR = 0.96, 95% CI 0.75, 1.24). The same pattern of association was seen be-
tween cigarette use and anxiety (unadjusted OR = 1.14, 95% CI 1.00, 1.30; fully adjusted
OR = 0.85, 95% CI 0.69, 1.04).
Table 3. Descriptives of confounders by frequency of cigarette use at age 16% (N).
Cigarette frequency age 16 Never 55.2 (988) Experimenter 35.0 (627) Weekly 4.3 (77) Daily 5.5 (99) P value
FH depression 25.8 (255) 28.9 (181) 28.6 (22) 34.4 (34) 0.044
FH schizophrenia 0.9 (9) 0.8 (5) 0 1.0 (1) 0.742
Maternal education1 74.8 (739) 75.0 (470) 79.2 (61) 80.8 (80) 0.189
Urban dwelling 88.7 (876) 89.0 (558) 90.9 (70) 86.9 (86) 0.925
Gender (female) 51.0 (504) 67.5 (423) 72.7 (56) 64.7 (64) <0.001
Borderline personality2 1.0 (10) 1.6 (10) 0 2.0 (2) 0.467
IQ at age 8 m(sd) 109.9 (15.2) 110.8 (15.3) 108.6 (14.2) 106.6 (16.7) 0.199
Psychotic experiences age 12 3.0 (30) 4.2 (26) 2.6 (2) 6.1 (6) 0.138
Conduct disorder3 5.3 (52) 7.0 (44) 9.1 (7) 13.1 (13) 0.001
Peer problems 7.6 (75) 5.7 (36) 1.3 (1) 12.1 (12) 0.661
Bullied 30.5 (301) 30.0 (188) 27.3 (21) 31.3 (31) 0.868
Cannabis age 164 5.0 (49) 47.2 (296) 73.3 (58) 88.9 (88) <0.001
Illicit drugs age 16 5.2 (51) 22.5 (141) 44.2 (34) 63.6 (63) <0.001
Alcohol use age 165 15.3 (151) 50.7 (318) 67.5 (52) 72.7 (73) <0.001
1No higher education. Categorised like this for purposes of presentation in this table only.
2Deﬁned as score of 4 or over, for the purposes of presentation in this table only.
3Early onset persistent group membership. Categorised like this for purposes of presentation in this table only.
4Ever used cannabis. Categorised like this for purposes of presentation in this table only.
5Hazardous alcohol use. Categorised like this for purposes of presentation in this table only.
doi:10.1371/journal.pone.0122896.t003
Table 4. Bivariate probit regression analysis of intensity of cannabis or cigarette use at 16 and depression and PEs at age 18 in the imputed
dataset.
N = 4345 Depression Psychotic Experiences
OR 95% CI p OR 95% CI p Wald test (p value)
Cannabis
1 1.34 1.18, 1.51 <0.001 1.38 1.23, 1.55 0.001 -0.023 (0.637)
3 1.29 1.13, 1.47 <0.001 1.41 1.24, 1.59 <0.001 -0.056 (0.292)
5 1.11 0.89, 1.38 0.343 1.12 0.91, 1.39 0.260 -0.010 (0.913)
Cigarettes
1 1.37 1.23, 1.53 <0.001 1.42 1.28, 1.57 <0.001 -0.018 (0.654)
3 1.24 1.10, 1.39 <0.001 1.33 1.19, 1.49 <0.001 -0.046 (0.307)
5 1.08 0.91, 1.28 0.367 1.15 0.98, 1.36 0.069 -0.043 (0.523)
Model 1—Case depression at 18 and suspected/deﬁnite PEs at 18 by unit increase of 4-level categorical cumulative cannabis use or frequency of
cigarette use at 16.
Model 3—as model 2 with additional adjustment for childhood confounders (borderline personality, IQ at age 8, PEs at age 12, conduct disorder trajectory
group membership, peer problems, bullied).
Model 5—as model 3 with additional adjustment for cigarette (or cannabis), alcohol and other illicit drug use.
doi:10.1371/journal.pone.0122896.t004
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Sensitivity analyses
In the complete case analysis, associations between cannabis and depression were of a larger
magnitude than in the imputed sample (S2 Table). Adjustment for cigarette use increased the
estimate size, and the fully adjusted OR was larger than the unadjusted. Associations between
cigarette use and depression were broadly similar to the imputed sample. Associations between
cannabis and anxiety and between cigarettes and anxiety were also broadly similar to the im-
puted sample (S3 Table).
Discussion
Intensity of cannabis use at age 16 was associated with an increased incidence of depression at
age 18. Adjusting for confounders assessed pre-birth and during childhood partly attenuated
the association with depression, although strong evidence for an association with depression
persisted. Further adjustment for cigarette, alcohol, or other drug use weakened the evidence of
association with depression, but also widened the confidence intervals around the effect esti-
mates. The strong correlation between cannabis use and other substances, particularly cigarette
use, may have led to collinearity problems with the statistical model, as evinced by the increase
in the size of the standard errors, and makes it difficult to interpret the results of cannabis inde-
pendently from those for other substance use.
In addition, investigation of cannabis users who claimed not to smoke cigarettes in our
study revealed that the vast majority of them (44 out of 47) used tobacco with their cannabis
and were thus still exposed to tobacco.[14] Therefore, our study (and almost certainly other
studies in countries where cannabis is smoked with tobacco that have adjusted for cigarette
smoking) will not have adequately adjusted for tobacco use. A further difficulty in interpreting
results adjusted for cigarette or other substance use is that it is feasible that use of these sub-
stances occurred secondary to the use of cannabis, for example through exposure to situations
where tobacco, alcohol or other drugs became more readily available. This is an example of
“collider bias”[36] and could have biased estimates of the association between cannabis and de-
pression.[37]
Cigarette use was also associated with an increased incidence of depression. However, ad-
justing for confounders measured pre-birth and during childhood attenuated the association
with depression to a greater extent than they did for cannabis and depression. Further adjust-
ment for cannabis or other substance use eliminated this association, though the same problem
of potential collider bias exists here too.
In contrast to our findings for depression, there was only weak evidence of associations be-
tween cannabis or cigarettes and anxiety, and these associations were eliminated after adjusting
for pre-birth and childhood confounders.
Whilst most results were similar in the sensitivity analysis using our smaller, non-imputed
(complete case) sample, one exception was that the association between cannabis and depres-
sion increased after adjustment for cigarette use. One explanation for this difference is that our
complete case analysis is biased as a result of non-differential attrition. Indeed the direction of
change in the estimate after adjusting for cigarette use is opposite to that expected given the re-
lationship between cigarette use and depression, and that between cigarette use and cannabis.
Our multiple imputation analysis is likely to be correcting for this to some extent as our impu-
tation model was carefully designed to try and accurately predict the missingness in
our variables.
The effect sizes we observed are consistent with previous meta-analyses that have reported
associations between cannabis use and later depression of a moderate-sized effect.[8, 9] Fur-
thermore, whilst we do not find evidence to support an association between cannabis use and
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incident anxiety we cannot exclude a small effect compatible with confidence limits from a re-
cent meta-analysis of association between cannabis use and anxiety.[38] Although authors of
that study attempted to assess the quality of included studies, estimating causal effect sizes
from meta-analyses of observational studies are inherently limited by inclusion of studies with
sub-optimal adjustment for confounding. For example, in Moore and colleagues’ meta-analysis
attenuation of unadjusted estimates was greater in studies that adjusted for the most compre-
hensive sets of confounders.[9]
Whilst research from post-mortem human brain,[39] neuroimaging,[40] and animal[41]
studies provide some evidence of plausible mechanisms by which cannabis might cause depres-
sion, this body of evidence is by no means compelling. For example, evidence from animal
models suggests that tetrahydrocannabinol (THC: a cannabinoid receptor type 1 (CB1) ago-
nist) during adolescence increases adult anhedonia and other models of depression and anxi-
ety,[42, 43] but there is also evidence that rimonabant (a CB1 antagonist) increases anxiety,
depression and suicidality.[44] Differences between acute and longer term effects of cannabis
on the brain have yet to be clearly elucidated, and have to incorporate evidence of euphoria
during acute intoxication with long-term adverse outcomes in cannabis users such as impaired
occupational and social function that might be expected to increase depression (though studies
of these outcomes are subject to the same problems of residual confounding as studies of de-
pression). Furthermore, whilst studies comparing the effects of cannabis strains with different
concentrations of THC, or different ratios of THC to cannabidiol (a cannabinoid that acts as a
CB1 antagonist) on depression and anxiety can potentially help with understanding of the
causal role of cannabis on these disorders, there are few such studies to date.[45]
Despite a common impression that the evidence supporting a causal effect of cannabis on
psychosis is stronger than that for depression we found no evidence that associations between
cannabis or cigarette use and depression were different to those between cannabis or cigarette
use and PEs in our bivariate analysis. Whilst it is possible that we did not have adequate power
to detect a difference, nevertheless our results suggest that associations between substance use
and mental health, if causal, seem to be non-specific, both in terms of substances and
outcomes.
There are a number of important limitations to our study. First, wave non-response and at-
trition (almost inevitable in a longitudinal study of this nature) means that our sample was
small compared to the original ALSPAC sample, and power to detect small effects was limited;
nevertheless our sample was still larger than most other cohorts that have examined the re-
search questions we address here,[9] and we used multiple imputation to reduce attrition bias.
It is possible that our imputation did not adequately address the missing at random assumption
and that bias from selective attrition persisted, or that higher-order confounding was present
and inadequately represented in the imputed models. However, imputed models are still likely
to be less biased than use of complete case data. Our exposure measures were based on self-re-
port data, which might be a limitation particularly for illicit drug use. If, for example, proneness
to depression made individuals more reluctant to admit to illegal drug use this may have led to
us underestimating the association between cannabis use and depression, though we have no
reasons to suspect this occurred. Our outcome measures were assessed via computerised inter-
view, therefore may not fully have captured depression or anxiety in the participants. However,
prevalence was equivalent to that expected from previous literature [46, 47]. Finally, the prob-
lem of co-occurrence of cannabis and tobacco in this and other studies to date has already been
discussed above, and would not be improved substantially by increasing sample size or having
more accurate measures of substance use. Identifying populations where individuals use canna-
bis without mixing it with tobacco may help address this limitation, though we are not aware
of any longitudinal studies in such populations currently. Utilising genetic variants associated
Longitudinal Associations of Cannabis and Cigarette Use and Depression
PLOS ONE | DOI:10.1371/journal.pone.0122896 April 13, 2015 9 / 13
with tobacco or cannabis use as instrumental variables in Mendelian randomisation analyses
offers a potential approach for determining whether cannabis or tobacco have causal effects on
psychopathology, but is limited by requirement of samples larger than currently available,[48]
and by the absence of genetic proxies for cannabis use.[49]
Conclusions
Whilst most associations we examined were explained to a substantial degree by confounders
assessed pre-term or during childhood, strong evidence of association between cannabis use
and depression persisted. However, interpreting results for cannabis or cigarette use indepen-
dent of each other is problematic, and our study highlights the limitations inherent in observa-
tional studies that aim to determine whether cannabis or tobacco use have causal effects on
psychopathology. Novel approaches are required to determine whether associations between
cannabis or tobacco and psychopathology are causal, and to help inform public knowledge and
health prevention policy.
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